Latest / Durham News Today | 2 Min News | The Daily News Now!
Freenome Soars on Cancer Test Breakthrough | Durham News
Freenome’s blood test for early cancer detection just went public with a massive 12% stock surge after Jefferies slapped a ‘Buy’ rating and $17 price target — signaling huge investor confidence. Their SimpleScreen colorectal test is poised for a U.S. launch this fall, backed by partnerships with Abbott and Roche, while their pipeline targets over ten cancers — including lung cancer with FDA Breakthrough status. The key? Offering a painless alternative to colonoscopies that could revolutionize early detection, improve survival rates, and slash healthcare costs — all while riding a long growth…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.